Noul
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Noul makes miLab™, a compact, toaster-sized device that automates blood and cancer diagnostic tests, including malaria screening, peripheral blood analysis, and cervical cell analysis, without requiring specialist laboratory staff.
It supplies this system to diagnostic laboratories worldwide, with a particular focus on small and mid-sized labs that lack the infrastructure or trained personnel for conventional microscopy-based testing. Listed on KOSDAQ, Korea's tech-focused small-cap board, Noul's platform runs its AI analysis entirely on the device itself, requiring no internet connection or cloud server.
Summary is AI-generated and may contain errors · figures from DART filings
Noul in five facts
What does Noul do?
Noul makes miLab™, a compact, toaster-sized device that automates blood and cancer diagnostic tests, including malaria screening, peripheral blood analysis, and cervical cell analysis, without requiring specialist laboratory staff.
Where is Noul listed and in which sector?
Noul (Korean name: 노을) trades under KRX code 376930 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Noul?
Its market capitalisation was US$9.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Noul's latest annual revenue and operating profit?
For fiscal year 2025, Noul reported revenue of US$3.9M, an operating loss of US$15.2M and a net loss of US$15.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 219.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Other market noticeOct 14
- Report on large shareholdings (5% rule) (standard)Sep 10
- Report on securities held by executives/major shareholdersSep 10
- Report on securities held by executives/major shareholdersSep 10
- Report on securities held by executives/major shareholdersSep 10
- Report on securities held by executives/major shareholdersSep 10
- Report on securities held by executives/major shareholdersSep 10
- Report on securities held by executives/major shareholdersSep 10
- Report on securities held by executives/major shareholdersSep 10
- Report on securities held by executives/major shareholdersSep 10
- Trading suspension liftedSep 4
- Trading suspension (share consolidation/split registration)
The Korea Exchange suspended trading in Noul Co., Ltd. common shares from 2026-08-20 until the day before the listing date of the replacement shares, due to a share consolidation.
M&A · Aug 14 - [Amended] Supply contract signed
Noul updated a previously disclosed supply contract with Lab Reagent Inc., now worth US$736K, about 68.6% of its recent annual revenue, running through Dec 2026.
Supply contract · May 15 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Noul reported consolidated results for FY2025: revenue of US$3.5M (+219.83% year on year), an operating loss of US$13.2M and a net loss of US$13.1M.
Earnings · Feb 9